Eli Lilly and Company (LLY) Stock

Eli Lilly has requested to participate in opposing a lawsuit filed by compounding pharmacies against the U.S. Food and Drug Administration. This lawsuit challenges the FDA's ruling that Lilly's popular weight-loss and diabetes medications are no longer in short supply.

In 2025, research and development innovation is expected to continue being a key priority. For those investing in the Large-Cap Pharmaceuticals sector, companies like Eli Lilly, Johnson & Johnson, AbbVie, AstraZeneca, and Pfizer are good options to keep in your portfolio.

The year has been challenging for both pharmaceutical companies, but developments in the last quarter increased the difference between them.

Eli Lilly (LLY) closed at $773.84 on the most recent trading day, showing a decrease of 1.19% from its previous closing price.

In 2024, stock splits have become a major trend in the market, with well-known companies like Nvidia and Walmart participating. Firms usually decide to split their stocks after experiencing significant growth to make their shares more affordable for more investors. This strategy helps attract a broader range of buyers.

If you want to find the best stocks, you don't have to start from scratch. The Securities and Exchange Commission makes it easy to keep track of the top investors in the world.

If you don't have time to check your stock portfolio frequently, it's essential to invest in stocks that won't create problems later. To achieve this, you should look for trustworthy companies that are growing.

It feels like it was only a short time ago that the medical community was focused on vaccines to fight the COVID-19 pandemic. Companies like Pfizer, Moderna, and Johnson & Johnson were frequently in the news for their important contributions to creating these vaccines.

The US Food and Drug Administration (FDA) has approved the first medication for obstructive sleep apnea.